HHS Won't Pursue Pharmacies Compounding Six Peptides Under New Interim 503A Policy

The federal government has given compounding pharmacies their clearest signal yet that they can prepare a short list of popular peptides without drawing FDA enforcement. On October 28, 2026, the Department of Health and Human Services filed a notice announcing an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, signed by Secretary Robert F. Kennedy Jr. and scheduled for publication in the Federal Register on October 30. The notice states that HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound drug products using any of six named peptides. It is a policy of enforcement discretion, not an approval, and HHS published it as a draft open to a brief public comment period while a slower rulemaking process continues.

What HHS announced

The action is a Notice of availability from the Office of the Secretary, carrying Docket No. HHS-OASH-2026-0496 and RIN 0910-ZD94, the same regulatory identifier that had been under White House review earlier in October. It was filed for public inspection on October 28, 2026 and is scheduled for publication in the Federal Register on October 30. The operative sentence is narrow and specific: to expand and improve patient access, HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in the policy's Appendix A. HHS ties the move to the Pharmacy Compounding Advisory Committee meetings and to data on peptide use, saying there is significant interest in compounding these substances given the lack of approved products.

Which peptides the policy covers

Appendix A lists six peptides: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. These are the same six that the FDA's Pharmacy Compounding Advisory Committee recommended for the 503A list at its July 2026 meeting, out of seven it reviewed; the committee voted against the seventh, emideltide (also called DSIP).

According to a regulatory analysis of the policy document, the enforcement discretion comes with conditions. It sets limits on the route of administration and on labeling, and it requires that the only drug delivery device co-packaged with or containing the compounded drug be an FDA 510(k)-cleared syringe, on the reasoning that more complex delivery devices add patient risk. The policy also defines each peptide's identity by features such as amino acid sequence, chemical structure, molecular weight, and molecular formula. The full conditions live in the HHS policy document rather than in the Federal Register notice itself.

Enforcement discretion is not approval

Enforcement discretion is a decision by the government not to pursue certain conduct. It is not FDA approval, and the notice is explicit that compounded drugs are not FDA-approved, meaning the agency does not review their safety, effectiveness, or quality before they are marketed. Nothing in the policy adds a peptide to the 503A bulks list, the roster of bulk drug substances that pharmacies may use in compounding under section 503A. That list is still being developed through notice-and-comment rulemaking, a process that can run for years, and HHS says its future rulemakings may propose adding some or all of these peptides based on the available evidence. The document states that it does not establish any rights for any person, is not binding on HHS or the public, and that HHS may revisit the interim policy in whole or in part if, among other things, a safety signal or product quality issue arises.

A break with FDA's own scientists

The advisory committee's July recommendations were just that, recommendations, and they ran against the advice of FDA's career review scientists, who had recommended against adding any of the peptides, citing gaps in safety characterization and clinical evidence rather than evidence of harm. A regulatory analysis of the new policy describes it as following the advisory committee members rather than the agency's scientists. The result is that an HHS-level enforcement decision now sits on top of an unresolved scientific disagreement inside the FDA, with the formal rulemaking that would settle the question still to come.

What it means for telehealth and patients

Peptides reach most consumers through telehealth and wellness clinics, so a policy that eases supply lands directly on that channel. Telehealth companies have said they would offer peptides if access loosened, and analysts have sized the potential market in the billions of dollars. For patients, the practical change is a clearer legal footing for obtaining these specific peptides by prescription through a licensed compounding pharmacy, rather than from research-chemical vendors that sell vials labeled not for human use. What has not changed is the evidence base: these peptides are not FDA-approved, the FDA has previously flagged peptides including BPC-157 for compounding risks such as contamination, allergic reactions, and effects on tumor growth, and much of the supporting data comes from animal studies rather than human trials. This is general information, not medical advice; anyone considering peptides should work with a licensed clinician and a verified compounding pharmacy that can provide a certificate of analysis.

The comment period and what comes next

HHS published the policy as a draft and is accepting written comments for two weeks after publication, through regulations.gov on Docket HHS-OASH-2026-0496. Several points remain open. The interim policy can be narrowed or withdrawn without rulemaking, the separate bulks-list rulemaking has not produced a proposed rule, and the legal footing is contested: industry groups have argued that the FDA cannot lawfully authorize compounding through an interim policy while rulemaking is pending, and the Partnership for Safe Medicines filed a citizen petition in October urging the agency to block compounding of unapproved peptides. These are the markers worth watching: the close of the comment period, any move toward a proposed rule on the 503A bulks list, any reported safety signal that would trigger a revisit, and any litigation challenging the approach.